Moving Pharmacogenetics Into Practice: It's All About the Evidence!

Area of Science:

• Pharmacogenetics
• Clinical implementation
• Evidence-based medicine

Background:

• Pharmacogenetics evidence has rapidly expanded, but consensus on clinical implementation standards is lacking.
• Diverse stakeholders, including patients, clinicians, and implementers, hold varying views on required evidence.
• Historical comparisons, like pharmacokinetics, offer insights into evidence evolution for clinical adoption.

Purpose of the Study:

• To review and synthesize different perspectives on the evidence needed for clinical pharmacogenetics implementation.
• To highlight the gap between patient-valued evidence and clinician reliance on randomized controlled trials (RCTs).
• To discuss future directions, including pharmacogenetic panels and educational needs.

Main Methods:

• Review of existing literature and resources curating pharmacogenetic evidence.
• Analysis of different types of evidence, focusing on RCTs and their limitations.
• Inclusion of patient cases and survey data to illustrate real-world impact and perspectives.
• Comparison with historical clinical implementation examples (e.g., therapeutic drug monitoring).

Main Results:

• Discrepancies exist in interpreting pharmacogenetic evidence across resources, though standardization efforts are ongoing.
• Patient surveys indicate high value for pharmacogenetic testing, with providers crucial for maximizing benefits.
• Clinicians and guidelines often prioritize RCT data, which may be impractical or unethical for pharmacogenetics.
• Implementers prioritize consistent evidence of pharmacogenetic associations.

Conclusions:

• Implementing pharmacogenetics in practice requires acknowledging diverse stakeholder viewpoints, especially the patient's.
• Recognition of evidence types beyond RCTs is crucial for broader clinical adoption.
• Standardization of evidence interpretation and increased education are necessary for advancing pharmacogenetics.